These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 37193706)

  • 41. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
    Planas D; Staropoli I; Michel V; Lemoine F; Donati F; Prot M; Porrot F; Guivel-Benhassine F; Jeyarajah B; Brisebarre A; Dehan O; Avon L; Boland WH; Hubert M; Buchrieser J; Vanhoucke T; Rosenbaum P; Veyer D; Péré H; Lina B; Trouillet-Assant S; ; Hocqueloux L; Prazuck T; Simon-Loriere E; Schwartz O
    bioRxiv; 2024 Feb; ():. PubMed ID: 38045308
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Determinants of Spike infectivity, processing, and neutralization in SARS-CoV-2 Omicron subvariants BA.1 and BA.2.
    Pastorio C; Zech F; Noettger S; Jung C; Jacob T; Sanderson T; Sparrer KMJ; Kirchhoff F
    Cell Host Microbe; 2022 Sep; 30(9):1255-1268.e5. PubMed ID: 35931073
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tracking SARS-CoV-2 variants during the 2023 flu season and beyond in Lebanon.
    Kodsi IA; Rayes DE; Koweyes J; Khoury CA; Rahy K; Thoumi S; Chamoun M; Haddad H; Mokhbat J; Tokajian S
    Virus Res; 2024 Jan; 339():199289. PubMed ID: 38036064
    [TBL] [Abstract][Full Text] [Related]  

  • 44. SARS-CoV-2 BA.1 and BA.2 breakthrough infections boost antibody responses to early Omicron subvariants but not BQ.1.1 or XBB.1.5.
    Abbad A; Yellin T; Singh G; Fried M; Raskin A; Tcheou J; Monahan B; Gleason C; ; Simon V; Carreño JM; Krammer F
    Cell Rep Med; 2024 Mar; 5(3):101474. PubMed ID: 38508136
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The spike receptor-binding motif G496S substitution determines the replication fitness of SARS-CoV-2 Omicron sublineage.
    Liang R; Ye ZW; Ong CP; Qin Z; Xie Y; Fan Y; Tang K; Poon VK; Chan CC; Yang X; Cao H; Wang K; Sun H; Hu B; Cai JP; Luo C; Chik KK; Chu H; Zheng Y; Yuen KY; Chan JF; Jin DY; Yuan S
    Emerg Microbes Infect; 2022 Dec; 11(1):2093-2101. PubMed ID: 35943779
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Temperature Influences the Interaction between SARS-CoV-2 Spike from Omicron Subvariants and Human ACE2.
    Gong SY; Ding S; Benlarbi M; Chen Y; Vézina D; Marchitto L; Beaudoin-Bussières G; Goyette G; Bourassa C; Bo Y; Medjahed H; Levade I; Pazgier M; Côté M; Richard J; Prévost J; Finzi A
    Viruses; 2022 Sep; 14(10):. PubMed ID: 36298733
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Key mechanistic features of the trade-off between antibody escape and host cell binding in the SARS-CoV-2 Omicron variant spike proteins.
    Li W; Xu Z; Niu T; Xie Y; Zhao Z; Li D; He Q; Sun W; Shi K; Guo W; Chang Z; Liu K; Fan Z; Qi J; Gao GF
    EMBO J; 2024 Apr; 43(8):1484-1498. PubMed ID: 38467833
    [TBL] [Abstract][Full Text] [Related]  

  • 48. SARS-CoV-2 Omicron XBB lineage spike structures, conformations, antigenicity, and receptor recognition.
    Zhang QE; Lindenberger J; Parsons RJ; Thakur B; Parks R; Park CS; Huang X; Sammour S; Janowska K; Spence TN; Edwards RJ; Martin M; Williams WB; Gobeil S; Montefiori DC; Korber B; Saunders KO; Haynes BF; Henderson R; Acharya P
    Mol Cell; 2024 Jul; 84(14):2747-2764.e7. PubMed ID: 39059371
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impact of mutations in SARS-CoV-2 recombinant sub-variant XBB.1.16 on the binding affinity with human ACE2 receptor.
    Tariq SS; Zia K; Nur-E-Alam M; Nerukh D; Farafonov VS; Ul-Haq Z
    J Mol Graph Model; 2024 Sep; 131():108813. PubMed ID: 38885553
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The rapid rise of SARS-CoV-2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants.
    Ao D; He X; Hong W; Wei X
    MedComm (2020); 2023 Apr; 4(2):e239. PubMed ID: 36938325
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of a highly conserved neutralizing epitope within the RBD region of diverse SARS-CoV-2 variants.
    Wang Y; Yan A; Song D; Duan M; Dong C; Chen J; Jiang Z; Gao Y; Rao M; Feng J; Zhang Z; Qi R; Ma X; Liu H; Yu B; Wang Q; Zong M; Jiao J; Xing P; Pan R; Li D; Xiao J; Sun J; Li Y; Zhang L; Shen Z; Sun B; Zhao Y; Zhang L; Dai J; Zhao J; Wang L; Dou C; Liu Z; Zhao J
    Nat Commun; 2024 Jan; 15(1):842. PubMed ID: 38287016
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2.
    Hu B; Chan JF; Liu H; Liu Y; Chai Y; Shi J; Shuai H; Hou Y; Huang X; Yuen TT; Yoon C; Zhu T; Zhang J; Li W; Zhang AJ; Zhou J; Yuan S; Zhang BZ; Yuen KY; Chu H
    Emerg Microbes Infect; 2022 Dec; 11(1):2275-2287. PubMed ID: 36039901
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3.
    Faraone JN; Qu P; Goodarzi N; Zheng YM; Carlin C; Saif LJ; Oltz EM; Xu K; Jones D; Gumina RJ; Liu SL
    Emerg Microbes Infect; 2023 Dec; 12(2):2270069. PubMed ID: 37819267
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors.
    Xia S; Wang L; Jiao F; Yu X; Xu W; Huang Z; Li X; Wang Q; Zhu Y; Man Q; Jiang S; Lu L
    Emerg Microbes Infect; 2023 Dec; 12(1):2178241. PubMed ID: 36748716
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines.
    Chalkias S; McGhee N; Whatley JL; Essink B; Brosz A; Tomassini JE; Girard B; Edwards DK; Wu K; Nasir A; Lee D; Avena LE; Feng J; Deng W; Montefiori DC; Baden LR; Miller JM; Das R
    J Infect Dis; 2024 Aug; 230(2):e279-e286. PubMed ID: 38349280
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neutralization sensitivity of SARS-CoV-2 Omicron variants FL.1 and GE.1 by therapeutic antibodies and XBB sera.
    Lee J; Naoe Y; Bang U; Nakagama Y; Saito A; Kido Y; Hotta A
    Virology; 2024 Jul; 595():110067. PubMed ID: 38653156
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A bispecific antibody exhibits broad neutralization against SARS-CoV-2 Omicron variants XBB.1.16, BQ.1.1 and sarbecoviruses.
    Wang Y; Hao A; Ji P; Ma Y; Zhang Z; Chen J; Mao Q; Xiong X; Rehati P; Wang Y; Wang Y; Wen Y; Lu L; Chen Z; Zhao J; Wu F; Huang J; Sun L
    Nat Commun; 2024 Jun; 15(1):5127. PubMed ID: 38879565
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multiple mutations of SARS-CoV-2 Omicron BA.2 variant orchestrate its virological characteristics.
    Kimura I; Yamasoba D; Nasser H; Ito H; Zahradnik J; Wu J; Fujita S; Uriu K; Sasaki J; Tamura T; Suzuki R; Deguchi S; Plianchaisuk A; Yoshimatsu K; Kazuma Y; Mitoma S; Schreiber G; Asakura H; Nagashima M; Sadamasu K; Yoshimura K; Takaori-Kondo A; ; Ito J; Shirakawa K; Takayama K; Irie T; Hashiguchi T; Nakagawa S; Fukuhara T; Saito A; Ikeda T; Sato K
    J Virol; 2023 Oct; 97(10):e0101123. PubMed ID: 37796123
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75.
    Wang Q; Iketani S; Li Z; Guo Y; Yeh AY; Liu M; Yu J; Sheng Z; Huang Y; Liu L; Ho DD
    Cell Host Microbe; 2022 Nov; 30(11):1512-1517.e4. PubMed ID: 36108630
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neutralization of SARS-CoV-2 Omicron subvariant BA.2.87.1.
    Lasrado N; Rössler A; Rowe M; Collier AY; Barouch DH
    Vaccine; 2024 Apr; 42(9):2117-2121. PubMed ID: 38458874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.